Generated October 15, 2026 at 8:33 PM ET
· Covers October 15 trading day
· 10 of 205 ready 8-Ks selected
· AI-assisted overview
Varonis Systems agreed to be acquired by Thoma Bravo-backed Proofpoint for $49.75 per share in cash, with the deal expected to close in the first half of 2027, while Beazer Homes stockholders approved the Dream Finders merger. Vivos Therapeutics agreed to issue $12 million in Series C convertible preferred shares for an at least 11% SOD Sciences stake and a 50% interest in pseudohypoxia test IP. FMC updated its Q3 2026 outlook to revenue of $65-125 million and Adjusted EBITDA of negative $510-565 million on $625-675 million of charges. Greenlane Holdings said four subsidiaries entered Florida assignment proceedings, and America's Car-Mart reported that lenders extended a default waiver to October 22 amid an active strategic alternatives review. Northrim Bancorp reported Q3 2026 EPS of $0.63 including an $8.8 million impairment, while Mustang Bio and Innovative Eyewear each disclosed Nasdaq bid-price grace periods and Anavex Life Sciences received FDA clearance of its Fragile X IND for blarcamesine.
GNLN
Greenlane Holdings, Inc.
other material
negative
materiality 0.85
October 15, 2026, 4:30 PM ET
Greenlane's four subsidiaries enter Florida assignment proceedings; court takes jurisdiction Oct 9
- Assignee Philip J. von Kahle filed petitions Oct 9, 2026 in Miami-Dade Circuit Court for Warehouse Goods, Greenlane Holdings LLC, KIM International and Kush Supply Co.
- Assignments for benefit of creditors under Chapter 727 of Florida Statutes were executed Sept 30, 2026 by the four units, all direct or indirect Greenlane subsidiaries.
- Case numbers: 2026-020549-CA-01 (Warehouse Goods), -020550, -020551 and -020552; Assignee seeks one consolidated docket led by Warehouse Goods; no judge assigned yet.
M&A
positive
materiality 1.00
October 15, 2026, 5:20 PM ET
Varonis Systems to be acquired by Thoma Bravo-backed Proofpoint for $49.75 per share in cash
- Varonis (VRNS) signed a Merger Agreement on Oct 15, 2026 with Proofpoint, Inc., a Thoma Bravo affiliate, and Vail Merger Sub, Inc.; each share converts to $49.75 cash.
- The Merger is expected to close in the first half of 2027; VRNS shares will be delisted from Nasdaq and deregistered under the Exchange Act.
- CEO Yaki Faitelson, who holds about 0.67% of shares, signed a Support Agreement to vote for the deal and will serve as a non-executive officer for 18 months after closing.
M&A
positive
materiality 0.90
October 15, 2026, 8:50 AM ET
Beazer Homes stockholders approve Dream Finders merger; closing expected within days
- Special meeting on Oct. 15, 2026 had 80.90% of votes entitled represented, constituting a quorum.
- Merger agreement approved: 21,541,108 votes for, 12,898 against, and 32,312 abstentions.
- Non-binding compensation proposal approved: 17,294,632 votes for, 4,275,714 against, and 15,972 abstentions.
VVOS
Vivos Therapeutics, Inc.
M&A
positive
materiality 0.90
October 15, 2026, 8:45 AM ET
Vivos Therapeutics to issue $12M Series C preferred for 11% SOD Sciences stake and 50% test co-ownership
- Vivos will issue 12,000 Series C Convertible Preferred shares with $1,000 stated value each, totaling $12 million, to SOD Sciences.
- Consideration includes 2,907,338 SOD common shares, at least 11% fully diluted, and a 50% undivided interest in SOD's pseudohypoxia test IP.
- Series C preferred is convertible at fixed $0.15 per share into up to 80 million common shares, subject to a 19.99% exchange cap.
regulatory
negative
materiality 0.60
October 15, 2026, 4:05 PM ET
Mustang Bio wins second Nasdaq grace period to April 12, 2027; reverse stock split possible
- Nasdaq staff granted MBIO an additional 180-calendar-day period, until April 12, 2027, to regain the $1.00 minimum bid price requirement.
- Company failed to regain compliance by the initial deadline of October 12, 2026, set after the April 15, 2026 deficiency notice.
- Original notice: common stock closed below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
LUCY
Innovative Eyewear Inc
regulatory
negative
materiality 0.60
October 15, 2026, 4:05 PM ET
Innovative Eyewear gets Nasdaq bid-price notice; has until April 7, 2027 to regain $1.00
- Received Oct. 9, 2026 notice from Nasdaq Listing Qualifications Staff; LUCY common stock closed below $1.00 for 30 consecutive business days, breaching Rule 5550(a)(2).
- Notice has no immediate effect on listing; 180-day cure period runs to April 7, 2027, requiring a $1.00+ closing bid for at least 10 straight business days.
- If uncured, company may qualify for a second 180-day period if it meets initial Nasdaq Capital Market criteria and signals intent to do a reverse stock split if needed.
AVXL
ANAVEX LIFE SCIENCES CORP.
regulatory
positive
materiality 0.60
October 15, 2026, 4:18 PM ET
Anavex gets FDA clearance of Fragile X IND for blarcamesine; Phase 2a in ~60 adults planned
- FDA notified Anavex on Oct 15, 2026 that it may proceed with its blarcamesine IND for Fragile X syndrome; the IND is now open for U.S. clinical study.
- Planned Phase 2a trial ANAVEX2-73-FXS-001: randomized, double-blind, placebo-controlled, dose-ranging oral solution in ~60 adult males with FXS.
- Primary endpoints are safety, tolerability and pharmacokinetics; secondary endpoints include Aberrant Behavior Checklist-FXS (ABC-FXS) and NIH Toolbox cognition.
CRMT
AMERICAS CARMART INC
other material
negative
materiality 0.85
October 15, 2026, 4:05 PM ET
Car-Mart lenders extend default waiver to Oct 22; strategic review active, bankruptcy risk cited
- Silver Point Finance as Agent and the Lenders extended the Scheduled Termination Date and relief on minimum liquidity and Collateral Coverage Ratio to Oct 22, 2026, from Oct 15.
- Company has experienced or expects events of default under the Oct 30, 2025 Credit Agreement, including failure to meet certain financial covenants and reporting obligations.
- Strategic alternatives review, overseen by a special committee of the board, remains active with third parties, the Agent and Lenders; no assurance any transaction results.
NRIM
NORTHRIM BANCORP INC
earnings
negative
materiality 0.75
October 15, 2026, 5:28 PM ET
Northrim Q3 2026 EPS $0.63, down from $1.20 YoY; $8.8M impairment on $20M Specialty Finance loan
- Q3 2026 net income $14.4M, or $0.63 per diluted share, vs $15.3M/$0.68 in Q2 2026 and $27.1M/$1.20 in Q3 2025; adjusted EPS $0.60.
- $8.8M pre-tax impairment (~$6.7M after-tax, $0.29/share) on a single $20.0M Northrim Funding Services relationship; resolution may take several quarters.
- Net interest income rose 5% QoQ and 10% YoY to $38.9M; NIMTE was 5.02%; total deposits grew 5% QoQ and YoY to $3.05B.
earnings
negative
materiality 0.92
October 15, 2026, 8:03 AM ET
FMC cuts Q3 2026 revenue to $65-125M, sees Adjusted EBITDA of -$510M to -$565M on $625-675M charges
- Q3 2026 revenue now expected at $65M-$125M with Adjusted EBITDA of negative $565M to negative $510M, an update to prior guidance.
- Commercial actions in Brazil, Argentina, the U.S. and Canada lower prices on select products held by channel customers; ~$625M-$675M of charges hit revenue and Adjusted EBITDA.
- FMC will modify its U.S. selling and pricing model, significantly reducing the gap between gross and net pricing versus the historical high gross-price/high-rebate structure.